Yi Chen, an analyst from H.C. Wainwright, reiterated the Buy rating on VolitionRX. The associated price target remains the same with $2.50.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yi Chen has given his Buy rating due to a combination of factors including VolitionRX’s recent strategic partnership and the potential for future growth. The company has entered into a significant agreement with Werfen, a leader in in vitro diagnostics, to out-license its Nu.Q NETs assay. This partnership is expected to leverage Werfen’s expertise and infrastructure, potentially leading to increased revenue through upfront and milestone payments, as well as future royalties.
Additionally, VolitionRX’s business model, which focuses on licensing revenue and consumable sales, is poised to benefit from expanding interest in its Nu.Q platform for cancer diagnostics. The company’s valuation, supported by a discounted cash flow analysis, suggests a price target of $2.50 per share. However, there are risks such as potential failures in clinical development and securing license agreements, which investors should consider.